Anaemia and Transplantation
Roche has a long term commitment to improving the success rate of organ transplantation while enhancing the health and quality of life of those who had a transplant.
CellCept (mycophenolate mofetil) is a Medicine used together with cyclosporin and corticosteroids to prevent the rejection of transplanted organs.
Anaemia is a decrease in the number of red blood cells or a reduction in their haemoglobin content. Haemoglobin is the pigment that carries the oxygen in the red blood cells - oxygen is required for the body to function. Anaemia has a wide variety of causes such as in chronic kidney disease, where the kidneys fail to produce the required amount of erythropoietin. Erythropoietin is the hormone that stimulates bone marrow to make red blood cells. Anaemia can also occur in premature infants and as a side effect of cancer treatment.
Roche focuses its activities in the area of renal anaemia with two of its leading products Mircera and Recormon.
Mircera is a novel continuous erythropoietin receptor activator indicated for the treatment of anaemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis. It is structurally different to other erythropoiesis-stimulating agents and provides stable and sustained haemoglobin levels with once-monthly maintenance dosing for all CKD patients currently treated with an ESA.
Recormon contains the active ingredient epoetin beta (recombinant human erythropoietin) a hormone that stimulates the production of red blood cells. Recormon is used to treat anaemia in people with kidney disease. Recormon is a solution for injection, available in pre-filled syringes containing 2000 and 5000 international units of epoetin beta.
Please note that Roche is unable to answer questions on individual disease treatment / management matters. These should be discussed with your doctor. As product information and availability varies from country to country, we are able to respond to Pakistan enquiries only. We cannot answer product-related questions through this website.
Following products are currently marketed by Roche Pakistan. The below information is a guide only.
What is Valcyte?
Valcyte is an anti-viral medicine that is prescribed to adult transplant patients who have a high chance of developing CMV disease after receiving a heart, kidney, or kidney-pancreas transplant.*
Valcyte is also prescribed to children (4 months to 16 years) who have a high chance of developing CMV disease after receiving a kidney transplant and to children (1 month to 16 years) who have a high chance of developing CMV disease after receiving a heart transplant.*
CMV is one of the most serious infections affecting transplant patients. Valcyte works by slowing the ability of CMV to reproduce itself within the body, helping
to prevent CMV disease in transplant patients.
CellCept® (mycophenolate mofetil) is a prescription medicine for people who have had a kidney, heart, or liver transplant. CellCept can help prevent rejection of the transplanted organ.
CellCept is used with other medicines called cyclosporines and corticosteroids. These medicines work together to prevent rejection of your transplanted organ.
What is organ transplant rejection?
Rejection happens when your immune system thinks your transplanted organ is foreign and attacks it.
During rejection, the transplanted organ doesn't work as well as it should. This doesn't mean that it will stop working completely, and it doesn't mean that you will always lose your transplanted organ. If you have any concerns or questions about organ rejection, talk to your transplant team.
CellCept is one of many anti-rejection medicines (also called immunosuppressive medicines) prescribed to help patients prevent rejection of their transplanted organ. After your transplant, you may take several of these medicines to suppress your immune system so that it won't attack your transplanted organ.
Recormon is epoetin beta (recombinant human erythropoietin: produced by recombinant DNA technology in CHRecormon is epoetin beta (recombinant human erythropoietin: produced by recombinant DNA technology in CHO cell line) indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in patients on dialysis and treatment of symptomatic renal anaemia in patients not yet undergoing dialysis.
MIRCERA is the first molecule of a new class of Continuous Erythropoietin Receptor Activators called methoxy polyethylene glycol-epoetin beta indicated for the treatment of anaemia associated with chronic kidney disease (CKD) including patients on dialysis and patients not on dialysis.
MIRCERA is administered less frequently than other erythropoiesis stimulating agents (ESAs) due to the longer elimination half-life.